Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

Keywords

Medicine, Gefitinib, T790M, Resistance (ecology), Oncology

References

• Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.Seiji Yano, Emiko Nakataki, S. Ohtsuka — 2005
• TNM Classification of Malignant Tumours, 7th EditionCh. Wittekind, Mary Gospodarowicz, Leslie H. Sobin — 2009
• The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.Masaki Tokumo, Shinichi Toyooka, Katsuyuki Kiura — 2005
• Resistance to gefitinibHidetaka Uramoto, Kenji Sugio, Tsunehiro Oyama — 2006
• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibTakayuki Kosaka, Yasushi Yatabe, Hideki Endoh — 2006
• “Rapid-Impact Interventions”: How a Policy of Integrated Control for Africa's Neglected Tropical Diseases Could Benefit the PoorDavid Molyneux, Peter J. Hotez, Alan Fenwick — 2005
• EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.Naruo Yoshimura, Shinzoh Kudoh, Tatsuo Kimura — 2006
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingJeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi — 2007
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainWilliam Pao, Vincent A. Miller, Katerina Politi — 2005
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram — 2005
• Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.Hidetaka Uramoto, Kenji Sugio, Tsunehiro Oyama — 2006
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysRaffaella Sordella, Daphne W. Bell, Daniel A. Haber — 2004
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858RChien‐Hung Gow, Jin‐Yuan Shih, Yih‐Leong Chang — 2005
• Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLCAristea Kalikaki, Anastasios Koutsopoulos, Maria Trypaki — 2008
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella — 2004
• Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond — 2004
• Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancerKatsuhiro Okuda, Hidefumi Sasaki, Haruhiro Yukiue — 2008
• Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutationNicholas W. Choong, Sascha Dietrich, Tanguy Y. Seiwert — 2006
• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.J. A. Engelman, Toru Mukohara, Kreshnik Zejnullahu — 2006
• Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smokingKenji Sugio, Hidetaka Uramoto, Kenji Ono — 2006

Cited by

• Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.Hidetaka Uramoto, Hidehiko Shimokawa, Takeshi Hanagiri — 2011
• EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.Yuxin Lin, Xian Wang, Hongchuan Jin — 2014
• 非小细胞肺癌个体化治疗相关分子标记物Guo N, Yu Chen, Changhai Yu — 2011
• 酪氨酸激酶抑制剂耐药机制及其治疗策略Jianbing Qiao, Wenping Chen — 2011
• 非小细胞肺癌T790M基因突变研究进展Hui Li, Shuang Zhang, Ying Cheng — 2013
• 45例晚期非小细胞肺癌EGFR-TKIs治疗获益后出现孤立进展后联合局部治疗的回顾性分析X Zhang, Bin Wang, Lin Lin — 2013
• 非小细胞肺癌中EGFR基因状态的检测对EGFR-TKIs疗效的预测价值Yuli Wang, Hongyu Liu, Jun Chen — 2010
• The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factorTakako Sano, Shinji Takeuchi, Takayuki Nakagawa — 2013
• Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.Jeryl Villadolid, Jennifer L. Ersek, Mei Ka Fong — 2015
• Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.Kenji Ono, Hidetaka Uramoto, Takeshi Hanagiri — 2010
• TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.Hidetaka Uramoto, Takamitsu Onitsuka, Hidehiko Shimokawa — 2010
• The expression of Ki-67, but not proliferating cell nuclear antigen, predicts poor disease free survival in patients with adenocarcinoma of the lung.Soichi Oka, Hidetaka Uramoto, Hidehiko Shimokawa — 2011
• Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples.Ying Wang, Wenlong Bao, Hua Shi — 2013
• Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung.Makoto Nakagawa, Hidetaka Uramoto, Hidehiko Shimokawa — 2011
• Clinical Significance of Epithelial-Mesenchymal Transition-Associated Markers in Malignant Pleural MesotheliomaTakashi Iwanami, Hidetaka Uramoto, Makoto Nakagawa — 2014
• Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.Shinji Takeuchi, Wei Wang, Qi Li — 2012
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase InhibitorsNeal I. Lindeman, Philip T. Cagle, Mary Beth Beasley — 2013
• Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase InhibitorsSei-Hoon Yang — 2013
• c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung CarcinomasKoji Tsuta, Yoshiki Kozu, Takahiro Mimae — 2012
• Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells.Ying Liu, Ying Yang, Yuanchao Ye — 2012

Related papers

• Re-treatment with Gefitinib for Non-small Cell Lung CancerYukiko Kusama, Tomonobu Koizumi, Michiko Itou — 2007
• Two Cases of Stage IV Lung Adenocarcinoma That Achieved a Long-term Survival on GefitinibFumi Karino, Saki Manabe, Shuji Murakami — 2015
• Recurrent gefitinib-induced interstitial lung disease.Masaru Suzuki, Hajime Asahina, Jun Konishi — 2008
• Gefitinib投与前より活性型EGFR遺伝子変異とEGFR-TKI耐性遺伝子変異（T790M）を認めた非小細胞肺癌の3例Toru Hiura, Yoshiki Hayashi, Tetsuya Abe — 2013
• EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib.Junichi Soh, Shinichi Toyooka, Shuji Ichihara — 2007
• Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer modelHiromi Hayakawa, Eiki Ichihara, Kadoaki Ohashi — 2013
• Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.Pasi A. Jänne — 2008
• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.J. A. Engelman, Toru Mukohara, Kreshnik Zejnullahu — 2006
• Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancerChengde Wang, Wei Wang, Chaoyang Wang — 2015